Indications & Uses
Cosentyx is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Plaque Psoriasis-1. Recommended dosage is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable.Psoriatic Arthritis-1. For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosage and administration for plaque psoriasis.2. For other psoriatic arthritis patients administer with or without a loading dosage. The recommended dosage: With a loading dosage is 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter Without a loading dosage is 150 mg every 4 weeks If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg. Ankylosing Spondylitis-1. Administer with or without a loading dosage. The recommended dosage: With a loading dosage is 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter Without a loading dosage is 150 mg every 4 weeks
Side Effects
Most common adverse reactions (greater than 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.
Cautions & Contraindications
Warnings & Precautions
Infections: Serious infections have occurred. Caution should be exercised when considering the use of Cosentyx in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue Cosentyx until the infection resolves.Tuberculosis (TB): Prior to initiating treatment with Cosentyx, evaluate for TB.Inflammatory Bowel Disease: Cases of inflammatory bowel disease were observed in clinical trials. Caution should be exercised when prescribing Cosentyx to patients with inflammatory bowel disease.Hypersensitivity Reactions: If an anaphylactic reaction or other serious allergic reaction occurs, discontinue Cosentyx immediately and initiate appropriate therapy.
Contraindications
Serious hypersensitivity reaction to secukinumab or to any of the excipients.